18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival G Polverari, F Ceci, V Bertaglia, ML Reale, O Rampado, E Gallio, ... Cancers 12 (5), 1163, 2020 | 91 | 2020 |
Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016 L Marandino, A La Salvia, C Sonetto, E De Luca, D Pignataro, C Zichi, ... Annals of oncology 29 (12), 2288-2295, 2018 | 87 | 2018 |
Quality of life analysis in lung cancer: a systematic review of phase III trials published between 2012 and 2018 ML Reale, E De Luca, P Lombardi, L Marandino, C Zichi, D Pignataro, ... Lung Cancer 139, 47-54, 2020 | 40 | 2020 |
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics L Mezquita, I Preeshagul, E Auclin, D Saravia, L Hendriks, H Rizvi, ... European Journal of Cancer 151, 211-220, 2021 | 36 | 2021 |
RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients U Malapelle, F Passiglia, C Cremolini, ML Reale, F Pepe, P Pisapia, ... European Journal of Cancer 146, 74-83, 2021 | 36 | 2021 |
Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon F Passiglia, V Bertaglia, ML Reale, MD Delcuratolo, F Tabbò, E Olmetto, ... Cancer Treatment Reviews 101, 102308, 2021 | 29 | 2021 |
Quality of life assessment and reporting in colorectal cancer: a systematic review of phase III trials published between 2012 and 2018 P Lombardi, L Marandino, E De Luca, C Zichi, ML Reale, D Pignataro, ... Critical reviews in oncology/hematology 146, 102877, 2020 | 23 | 2020 |
Immune-checkpoint inhibitors combinations in metastatic NSCLC: new options on the horizon? F Passiglia, ML Reale, V Cetoretta, S Novello ImmunoTargets and therapy, 9-26, 2021 | 22 | 2021 |
Resistance to anaplastic lymphoma kinase inhibitors: knowing the enemy is half the battle won F Tabbò, ML Reale, P Bironzo, GV Scagliotti Translational lung cancer research 9 (6), 2545, 2020 | 19 | 2020 |
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma M Tagliamento, P Bironzo, H Curcio, E De Luca, D Pignataro, SG Rapetti, ... Critical Reviews in Oncology/Hematology 172, 103639, 2022 | 18 | 2022 |
Quality-Of-Life assessment and reporting in prostate cancer: systematic review of phase 3 trials testing anticancer drugs published between 2012 and 2018 L Marandino, E De Luca, C Zichi, P Lombardi, ML Reale, D Pignataro, ... Clinical Genitourinary Cancer 17 (5), 332-347. e2, 2019 | 18 | 2019 |
Early progression in non-small cell lung cancer (NSCLC) with high PD-L1 treated with pembrolizumab in first-line setting: a prognostic scoring system based on clinical features A Passaro, S Novello, D Giannarelli, E Bria, D Galetta, A Gelibter, ... Cancers 13 (12), 2935, 2021 | 16 | 2021 |
An examination of two dichotomies: women with lung cancer and living with lung cancer as a chronic disease T Vavalà, M Rigney, ML Reale, S Novello, JC King Respirology 25, 24-36, 2020 | 15 | 2020 |
Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective U Malapelle, S Pilotto, F Passiglia, F Pepe, P Pisapia, L Righi, A Listì, ... Critical Reviews in Oncology/Hematology 160, 103300, 2021 | 13 | 2021 |
68Ga-PSMA uptake in fibrous dysplasia ML Reale, C Buttigliero, M Tucci, R Giardino, C Poti Clinical nuclear medicine 44 (6), e396-e397, 2019 | 13 | 2019 |
Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients U Malapelle, S Pilotto, ML Reale, F Passiglia, P Pisapia, F Pepe, ... Critical Reviews in Oncology/Hematology 169, 103536, 2022 | 12 | 2022 |
Time trends in health-related quality of life assessment and reporting within publications of oncology randomised phase III trials: a meta-research study L Marandino, F Trastu, E Ghisoni, P Lombardi, A Mariniello, ML Reale, ... BMJ ONCOLOGY 2 (1), 1-9, 2023 | 11 | 2023 |
Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients ML Reale, R Chiari, M Tiseo, F Vitiello, F Barbieri, D Cortinovis, ... Lung Cancer 140, 71-79, 2020 | 11 | 2020 |
Gender differences in lung cancer T Vavalà, A Mariniello, ML Reale, S Novello Journal of Sex-and Gender-Specific Medicine 2 (3), 99-109, 2016 | 11 | 2016 |
Analysis of the adequacy of control arms in oncology randomised clinical trials published between 2017 and 2021: a meta-research study A Rossi, G Aimar, M Audisio, M Bungaro, A Caglio, R Di Liello, T Gamba, ... European Journal of Cancer 189, 112920, 2023 | 10 | 2023 |